Adimab LLC’s tech transfer deals with GlaxoSmithKline PLC and Biogen Inc. represent the small biotech’s greatest business development and financial successes to date, and confirm that with the right technology, it’s possible to build a successful and rapidly profitable company whose own ambitions begin and end at drug discovery.
Adimab Discovers Sustainable Profitability Through GSK, Biogen Deals
The antibody engineering company Adimab LLC has signed two non-exclusive deals that should put the small biotech firmly in the black. The deals with GSK and Biogen, announced July 26, are Adimab’s first in which it transfers its technology for broad use by partners.